Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07463651) titled 'MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Acute Myeloid Leukemia (AML)
FLT3-ITD Mutation
Allogeneic Hematopoietic Cell Transplantation (HCT)
Maintenance Therapy
Gilteritinib
Sorafenib
Intervention:
Drug: Gilteritinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: May 1, 2026
Target Sample Size: 594
To know...